In this video, InMed CEO Eric A. Adams speaks with BTV about InMed’s focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company’s proprietary biosynthesis platform with potential to manufacture pharmaceutical-grade, high-yield cannabinoids.
Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s